A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs
Portfolio Pulse from Benzinga Insights
In the past three months, 9 analysts have provided mixed evaluations for Immunocore Holdings (NASDAQ:IMCR), with a range of ratings from bullish to bearish. The average 12-month price target has decreased by 12.22% to $79.11. Analysts have adjusted their ratings and price targets, reflecting their views on the company's current state. Immunocore Holdings, a biotechnology company, has shown a 26.18% revenue growth rate but lags behind industry peers. The company maintains strong financial health with efficient cost management and a balanced debt approach.
October 24, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunocore Holdings (NASDAQ:IMCR) has received mixed analyst ratings, with a decrease in the average price target by 12.22% to $79.11. The company has shown a 26.18% revenue growth but lags behind industry peers. Analysts have adjusted their ratings and price targets, reflecting their views on the company's current state.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on IMCR's stock price. The company's revenue growth is positive but not as strong as its peers, which may limit upward momentum. The adjustments in ratings and price targets reflect analysts' cautious stance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100